AbbVie is committed to making a positive impact in the fight for racial justice. To address the ongoing issues in our criminal justice system, we’ve donated $5 million to the NAACP Legal Defense and Education Fund and the Equal Justice Initiative. Over the next five years, we are partnering with nonprofits in our communities to donate an additional $50 million.
AbbVie’s acquisition of Allergan accelerated our efforts in delivering groundbreaking medicines around the world. We’re investing more into research and development, expanding into new therapeutic areas and transforming the opportunities ahead.
AbbVie is committed to addressing the COVID-19 public health crisis. We’ve partnered with health authorities and institutions to accelerate R&D into treatment and prevention. Additionally, AbbVie donated $35 million to underserved communities and healthcare systems.
From collaborating in clinical research to providing equipment and supplies, we’ll continue to keep the health and safety of communities and our employees at the forefront of our efforts.
Discovered and developed in AbbVie’s labs, RINVOQ™ (upadacitinib) was granted FDA approval in the U.S. for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate, marking our second FDA approval of a targeted immunomodulator (TIM) therapy in 2019. This milestone has helped many people living with RA achieve clinical remission or low disease activity and continues our long-standing commitment to advancing the treatments available for people living with immune-mediated conditions.
Corporate responsibility is a critical part of who we are as a company, which is why we were delighted to be ranked 17th on CR Magazine’s annual 100 Best Corporate Citizens List. This influential list recognizes outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies.
AbbVie’s SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, received both FDA and European Commission approvals for the treatment of severe plaque psoriasis, a chronic condition affecting 125 million people worldwide.
AbbVie donated $40 million to fund the rebuilding of the district’s only middle school, Neal Math and Science Academy, to help improve student success and graduation rates, reduce dropout rates and increase college and career readiness. The middle school capped off our $350 million nonprofit charitable contribution pledge in 2018 and built on our longstanding commitment to investing in North Chicago.
AbbVie was granted accelerated approval for a treatment for newly-diagnosed AML in adults 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy. AML is one of the most aggressive blood cancers, and this new approval marked a significant milestone for patients diagnosed with this disease.
This contribution, the largest single donation in both AbbVie and Ronald McDonald House Charities history, provided essential support such as housing, meals and education for hospitalized children and their families across America.
We received the first FDA approval in over a decade for an oral treatment of the moderate-to-severe pain associated with endometriosis, one of the most common gynecologic disorders in the U.S.
In 2018, we were proud to be featured in the FORTUNE 100 Best Companies to Work For list for the first time. At AbbVie, culture has always been a strategic priority, and our employees are unified by a commitment to make a remarkable impact on patients’ lives.
Nearly half of transplant patients develop chronic graft-versus-host-disease, or cGVHD, in which the donor's immune cells damage the patient's normal organs and their quality of life. Learn more from Lori Styles, M.D., senior medical director, Pharmacyclics, an AbbVie company.
Reputation Institute Global Pharma RepTrak® named AbbVie the 2017 Most Reputable Pharmaceutical Company, based on more than 16,500 reputation ratings collected among the general public in Brazil, Canada, France, Italy, Germany, Spain, United Kingdom and the United States.
The company moved to 2nd on the list, up from 32 in 2016.
For the third year in a row, AbbVie placed highly on the Dow Jones Sustainability World Index, which measures performance of the world’s largest companies based on long-term economic, environmental, and social criteria and business practices that create long-term shareholder value. In 2016, we had the highest industry score on 12 of 22 criteria.
We received a new approval for our biologic treatment for non-infectious uveitis, an immune-mediated disease that can flare and impair vision.
With the opening of our 43,000-square-foot Cambridge Research Center in Massachusetts’ biotech corridor, we expanded our neuroscience research, including Alzheimer’s disease.
By earning these approvals in the United States and European Union, we furthered our commitment to tackling the world's toughest diseases.
Considered to be the biomedical industry's highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies. Worldwide, the Prix Galien Award is generally regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
Working Mother magazine recognized AbbVie among its “Working Mother 100 Best Companies” for the third consecutive year. This recognition is given for outstanding leadership in creating progressive programs, advancement of women, flexibility, childcare and paid parental leave for employees like Sandra.
We received the first U.S. FDA approval for HS, a chronic inflammatory skin disease.
The FDA approved our medicine for the treatment of motor fluctuations for people with advanced Parkinson's disease.
The first medicine developed independently by AbbVie, VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets), was approved in the United States.
With a new indication approval in the United States, we had collectively served over 30 million patients worldwide with our medicines.
We joined forces with Calico, Alphabet’s life sciences research company, to tackle health issues that affect the world's aging population.
What started in 2014 as a primarily headquarters-based week of service involving a thousand employees, has since become a global AbbVie tradition with more than 7,000 employees in nearly 60 countries. See the impact of our Week of Possibilities around the world.
Our new company needed its own culture, and we quickly got to work implementing changes that would drive performance and success through our business, our culture and our remarkable impact. Find out how we built “The AbbVie Way,” and what it means to truly live it.
After less than a year of existence, AbbVie ranked 4th on Science magazine's annual list of Top Science Employers, as surveyed by more than 3,000 respondents.
With 71 million people worldwide infected with hepatitis C (HCV), our ongoing commitment to those living with the virus means understanding their journey. That's why we were thrilled when the FDA gave us this designation, intended to expedite the development and review of drugs for serious or life-threatening conditions, for our investigational HCV regimen.
The first batch of AbbVie-branded HUMIRA® (adalimumab) pens rolled off the production line. Within 24 hours, approximately 23,000 finished cartons – 46,000 pens – had been made for patients in the United States.
On January 2, 2013, we rang the opening bell on the New York Stock Exchange to mark our first official day as a new biopharmaceutical company. With an initial stock price of $34.40 per share, we hit the ground running, solidifying our patient-centered mission and began creating our culture of agility and accountability.
